Charles River Laboratories International, Inc. (CRL)
| Market Cap | 10.39B |
| Revenue (ttm) | 4.03B |
| Net Income (ttm) | -184.65M |
| Shares Out | 48.17M |
| EPS (ttm) | -3.76 |
| PE Ratio | n/a |
| Forward PE | 18.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,445,803 |
| Open | 210.00 |
| Previous Close | 212.71 |
| Day's Range | 210.00 - 217.19 |
| 52-Week Range | 144.26 - 228.88 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 215.33 (-0.19%) |
| Earnings Date | Aug 5, 2026 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $215.33, which is a decrease of -0.19% from the latest price.
News
Charles River to collaborate with AI/ML drug discovery platform Lilly TuneLab
The company states: “Charles River (CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (LLY). TuneLab was created to acce...
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery pl...
Charles River upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Charles River (CRL) to Overweight from Equal Weight with a price target of $220, up from $185. With a strong uptick in biopharma funding beginning to transition…
Charles River Laboratories International Transcript: Jefferies Global Healthcare Conference 2026
Leadership transition drives a new strategy focused on simplification, margin improvement, and growth, with significant divestitures and cost savings underway. Investments in AI and NAMs support efficiency and animal reduction, while demand stabilizes and manufacturing margins are set to recover above 30%.
Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will partici...
Charles River Laboratories International Transcript: 46th Annual William Blair Growth Stock Conference
The presentation outlined a strategy focused on operational efficiency, portfolio refinement, and technology-driven growth, including AI and NAMs. Financial guidance was reaffirmed, with expectations for margin expansion and renewed organic growth. The company is strengthening its global position, especially in China, and remains a leader in drug development innovation.
Charles River Laboratories International Slides: 46th Annual William Blair Growth Stock Conference
Charles River Laboratories International has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.
Charles River upgraded to Outperform from Hold at CLSA
CLSA upgraded Charles River (CRL) to Outperform from Hold with a price target of $219, up from $167. The firm sees a more “constructive regulatory tone” in both China and…
Charles River Associates (CRA) to Present at Noble Capital Markets Virtual Conference
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will partici...
Charles River, Medipost sign non-exclusive MoU to advance GMP testing solutions
Charles River (CRL) Laboratories and Medipost have entered into a strategic, non-exclusive Memorandum of Understanding to collaborate on GMP-compliant testing, as well as broader commercial and market...
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU...
Charles River announces ‘continued momentum’ in digital pathology platform
Charles River (CRL) Laboratories International announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timeli...
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to...
Charles River price target raised to $220 from $200 at Evercore ISI
Evercore ISI raised the firm’s price target on Charles River (CRL) to $220 from $200 and keeps an Outperform rating on the shares.
Charles River price target raised to $213 from $200 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Charles River (CRL) to $213 from $200 and keeps an Outperform rating on the shares. The firm updated its model…
Charles River price target raised to $192 from $175 at Mizuho
Mizuho raised the firm’s price target on Charles River (CRL) to $192 from $175 and keeps a Neutral rating on the shares.
Charles River price target raised to $220 from $210 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Charles River (CRL) to $220 from $210 and keeps an Overweight rating on the shares.
Charles River Laboratories International Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue of $996M (+1.2% YoY), but organic revenue declined 1.5% and EPS fell 12% to $2.06. Strategic portfolio actions and cost savings are expected to drive 120-150 bps margin expansion in 2026, with most improvement in the second half.
Charles River Laboratories International Earnings release: Q1 2026
Charles River Laboratories International released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Charles River Laboratories International Slides: Q1 2026
Charles River Laboratories International has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Charles River Laboratories International Quarterly report: Q1 2026
Charles River Laboratories International has published its Q1 2026 quarterly earnings report on May 7, 2026.
Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fisc...
Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that its Board of Directors ha...